NICE recommends pembrolizumab
The National Institute for Health and Care Excellence (NICE) recommends pembrolizumab (Keytruda; Merck, Sharp & Dohme) as a treatment option in adults with advanced melanoma that has not been previously treated with ipilimumab when the company provides pembrolizumab with the discount agreed in the patient access scheme.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200193
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com